We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Bionostics | LSE:BIO | London | Ordinary Share | GB0008381823 | ORD 25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 29.75 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
24/4/2007 11:39 | Aquilla Yes I do. Will be holding for another year. The mess has now been cleared and we should see a profitable company in the future. Yes the second half has started strongly which was nice to hear. Will try to send you some further info. | the hog | |
24/4/2007 09:04 | Results more or less what I expected. BIO slipped into loss the first half but its good to see that the second half has started strongly. I seem to be talking to myself...anybody else own these shares?? | aquilla | |
20/4/2007 04:47 | Results next week, on the 24th, which is ironic as the share price seems stuck on 24p at the moment. Hopefully,The Hog, those good results will materialise, but bearing in mind the previous company announcements (listed under Ferraris) I'm expecting mixed results for the first half with some positive guidance for the current half year. | aquilla | |
04/4/2007 05:35 | The share price has been going sideways for the last few weeks with 24.5p the resistance point. Will we now see a breakout as we approach the interims due later this month? | aquilla | |
20/3/2007 13:34 | aquilla It's true they do have a lot of debt. They have now sold off their loss making divisions and are concentrating on their 2 remaining. Currently they have a good revenue stream from them and their overhead has now decreased. I would expect good results to come. | the hog | |
19/3/2007 15:11 | Good to see the price increase on the back of some decent volume. | aquilla | |
15/3/2007 16:52 | The Hog.. from a broker? On valuation grounds they have got a lot of debt, but much depends on how the two remaining divisions (in particular IVD) have been performing...interim | aquilla | |
15/3/2007 11:04 | Well undervalued Expect a share price target of 40p. I've heard this from a good source. | the hog | |
12/3/2007 17:33 | Exceptional amount of activity today on no news - more trades in one day than FER had in a year!! As the price has risen perhaps one can deduce that the next news will be positive? | gelp | |
12/3/2007 09:19 | Nice to see this spiking up. I'm in Plasmon as well and it went up 40% on Friday and another 25% today (so far) on news of a placing and that Hanover, the recovery specialists, would be taking a 24% stake and a seat on the board. Invesco Perpetual will also have a 29% stake. I was wondering, just wondering, if a similar scenario could apply here.... :-) IMHO DYOR | aquilla | |
16/2/2007 08:46 | I have been in and out during the Ken Baker days and have also rebought again now. Pleased to see Michael Thomas buying in at 34.25! Presumably we shall see the overheads slashed & either profits up or a take out. The business is now far too small to be on the main listing unless some serious activity is envisaged to grow the business. There is not a lot to go on at the moment except that the Chairman has previously apparently 'increased shareholder value' Good luck to him here! The net assetts are shown as 7.43 mil, and profits 1 mill on sales of 14mill. If that is in fact after disposals and after interest on £10mill plus? & pension deficit?then EBITA could be 2 mill. That may be optimistic but we do not know what the budget going forward looks like and some of the advfn data may be out of date - though I would have thought some are should be taken to inform everyone of all material facts etc etc. | gelp | |
16/2/2007 06:24 | Nobody's set up a thread for Bionostics (formerly Ferraris) so I thought I'd get the ball rolling. I got back in at around 23p three weeks ago, having sold out ages ago, hoping this was near the bottom.They have disappointed for some years now and the graph looks grim, but they have got a new ceo, Michael Thomas, who has over 30 years' experience in pharmaceutical, biological, drug delivery system and biotechnology industries. He joined from Argea LLC, the US based management services company, where since 2003 he had been Executive Vice President and Senior Partner. He was the President and Chief Executive Officer of Glycodesign Inc, the Toronto Stock Exchange quoted pharmaceutical company, where he oversaw its successful restructuring and revitalisation and a significant improvement in shareholder value. A month after joining Bionostics (Ferraris as it then was) he bought 100000 shares at 34.25 pence each (back in October). Edit: I've since been told he was awarded these shares. Bionostics has got rid of the two loss-making divisions, keeping the two traditonally profitable ones, IVD and OC. The company did announce that IVD had started the year more slowly but a more recent announcement said that new contracts would partially mitigate this. It still has considerable debt, though this has been greatly reduced by the two sales. | aquilla | |
14/11/2006 14:47 | Post removed by ADVFN | Abuse team | |
28/4/2006 02:35 | ABOUT THE LECTURE: Farmers may be filling our tanks and heating our homes in coming years, if Lee Lynd's vision pans out. Evolving technology can transform feedstocks like corn and soybeans as well as perennial grasses into energy and power. What he describes as "cellulosic biomass" holds the promise of replacing much of the fossil fuel we depend on, with a large number of positive side effects, according to Lynd's complex equations. The biomass conversion process has "near-zero net greenhouse emissions," because "before you return carbon dioxide to the atmosphere from a biofuel, you first have to remove it from the atmosphere in photosynthesis." Another benefit: perennial grass may be grown both for livestock feed and for fuel, and when harvested, adds to soil fertility. Lynd allays concerns that a conversion to biofuels would lead to inadequate acreage for all of our resources needs, from food to biodiversity. If farmers integrate their crops to maximize both food and energy needs, and if vehicle efficiency improves, very little new land would be needed. "If we're prepared to act as if this is important," says Lynd, we can supply the U.S. mobility demand from biomass within the land currently allocated to agriculture." We "can bury our heads in the sand," says Lynd and try to "pretend that our energy challenges are not real," or even pray for a miracle, but in his view, the best bet for securing a sustainable and secure energy future lies in innovation and change. VIDEO: | energyi | |
29/3/2006 09:57 | LONDON (AFX) - Compact Power Holdings PLC said it has reached agreement with Balkan General Engineering (BGE) of Greece that will allow the construction of a new waste to energy plant at Avonmouth Bristol to commence. Project work is expected to begin shortly and the plant is expected to become operational in the autumn of 2007, it said. The new plant will process some of Bristol City Council's non-recyclable municipal waste from which it will produce renewable heat and power. It will also be able to process a wide range of other wastes. The plant will be designed to process up to 30,000 tonnes a year of municipal waste and generate up to 3.6 Megawatts of electricity and 15 Megawatts of usable heat. Compact Power said it expects to receive fees in connection to the construction of the new plant of around 3.9 mln stg over the next 13 months. In addition once the new plant is operational, Compact Power will be entitled to ongoing fees and rent of approximately 500,000 stg a year, it said. Compact Power has granted to BGE 5 year warrants to subscribe for up to 1,200,000 ordinary shares in Compact Power exercisable at 30 pence per share in connection with the deal. newsdesk@afxnews.com jlw COPYRIGHT Copyright AFX News Limited 2005. All rights reserved. The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News. AFX News and AFX Financial News Logo are registered trademarks of AFX News Limited | asparks | |
20/2/2006 10:01 | 2 companies worth a look LSE:GTL LSE:RVA | asparks | |
25/10/2005 18:23 | don't understand how the glpg shares on the euronext are trading at 9.5 euro's a sterling price of £6.41p yet the Aim glpg shares are trading at £5.35p or 7.92 euro's why sell at the discounted rate someone is making an error there !!! still haven't got my glpg shares yet happy to wait as the new enlarged company has plenty to offer the market soon, will be happy when the two stocks are trading at/ on a level playing field. alpha. | alpha534u | |
25/10/2005 14:54 | hastings: hello -yes, of course! No news, very small volume of sells is no reason for me to jump ... though of course anything could happen. BTW, I've a thread here on SCT John | jonwig | |
25/10/2005 14:29 | jonwig OT are you still holding SCT? | hastings | |
25/10/2005 12:44 | Got my GLPG stock just now and sold at 545p - small profit. Don't take that as a comment on the merits of the company: it's just that I want the money elsewhere. Looking back, my mistakes were (i) accepting the bid, rather than selling in the market and (ii) not realising that the upward move in the GLPG share price through Sept and Oct was most likely a bit of shrewd financial engineering which is being unwound. | jonwig | |
20/10/2005 11:23 | GLPG at 600p to sell in London which equates to a BIO price of 135p compared with BIO sell quote of 125p. Amsterdam quote of Galapagos is 10euro which at 1.4756e = £1 equates to 677p = 152p for BIO. What will happen between now and when we camn get our hands on the shares? | vector | |
18/10/2005 12:06 | jonwig, I suspect there will be quite a few BIO holders wanting to sell as soon as they get hold of their shares and I guess that the price now quoted for GLPS probably anticipates that. My BIO shares are held in a nominee account and my Broker tells me that it will be late next week before I would be able to sell them. MJ | mjcrockett | |
18/10/2005 10:25 | The current Eur10.15 of GLPG equates to 696p, as opposed to the AIM quote ('WI') of 640p. I'd expect to see convergence on Thursday, when GLPG are fully listed. Even the 640p makes the BIO bid worth 144p. | jonwig |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions